Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (10502)	6/18/1999 12:26:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Cacacito, thanks so much for the analysis. I have thought of a motive for not telling us the trial has been concluded, if that is the case. The motive would be to make what someone considers a blockbuster announcement which combines the I-Prex deal with Trauma trial termination. REMEMBER EVERYONE THIS IS SIMPLY A MENTAL EXERCISE. MAKE ALL YOUR BUY AND SELL DECISIONS BASED ON THE POST OF ROBERT K UNLESS HE TELLS YOU OTHERWISE. I oppose waiting to combine the announcements. However there is another reason for the combination. As independent releases each is picked to pieces and made to seem less important. The result is less of a market impact than one would expect. But when two variables are combined in the same release the mind accepts the entire message as super positive.<g> At any rate whenever XOMA stops providing accrual data on any future trial, I am going to posit that the trial has been halted. <g>

To: Cacaito who wrote (10502)	6/21/1999 10:08:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

The P II Trauma trial dosage for the first 400 was 4 mg per Kg of weight for 2 days. In the continued phase of P II I believe they tried some different dosage regimes. One I have seen for Jan of 98 mentioned 3 days. My question is do we know what dosage is being used and for how many days in the P III trial. Admit I don't know what mental use I will make out of this information but I would like to know nonetheless. From a lay persons view even understand that at times less is more, in general it is had knot to believe that more and longer is better. Will probably ask Martin, if there is no answer already available. The ISS scores for the treatment arm were a lot lower than for the placebo arm so it is not that clear how significant the positive results were. Why not a continuous infusion? Why just two days? Is the threat of infection and endotoxin over in two days? Is it not cost effective to do more? Will certain conditions be treated differently? Just searching for questions that make sense and will shed some light on benefit to the patient, and market for the product. Obviously for chronic conditions XOMA is already looking for ways to provide the drug on a continuos basis. Perhaps an acute condition is taken care of in two days, three days and thats that. ????

To: Cacaito who wrote (10502)	6/21/1999 10:39:00 AM
From: aknahow	Respond to of 17367

Cacaito, see the 1998 'last update", date and the reference to 3 days. This does not mean I am sure it refers to P III. Provided only to show the background for my question. The Pharmacokinetic and Immunological Effects of two Treatment Regimens of Bactericidial/Permeability-Increasing Protein in Patients With Hemorrhage Due to Trauma Principal Investigator: Seth Izenberg, M.D. Sponsor: XOMA Corporation Volunteers Gender: Male or Female Age: Adults Eligibility: Trauma who receive 2 units of blood Exclusions: Spinal cord injury, head injury, abdominal cancer Description of Research: Protein that causes bacteria cell wall to become permeable allowing study drug and antibiotics to kill bacteria. Drug is given IV over 3 day with PK sample collection. Study is placebo controlled. USA Protocol Number: 96-184 Primary Disease Category: Trauma Keyword(s): Blood loss, trauma Experimental Drug/Device: Bactericidial/permeability-increasing protein CONTACT/REFERRAL INFORMATION: Physician referrals are encouraged: YES Patient inquiries are encouraged: YES For more information about this research please contact: Name: Cathy Blache/Tootie Wright Email: None Address: 2451 Fillingim Street Surgery Department Mastin 700 Mobile, AL 36617 Phone: (334)471-7988 Fax: (334)470-5827 University of South Alabama Clinical Trial Information (last update 1/27/98) To the Investigators Page \| To the Department/Specialty Page To the Clinical Trials Homepage \| To the College of Medicine Homepage